<DOC>
	<DOCNO>NCT00679835</DOCNO>
	<brief_summary>This research study design look pharmacokinetics ( distribution , breakdown , removal ) tolerability single dose daptomycin patient age 2 6 year infection cause specific group bacteria ( call Gram-positive bacteria ) .</brief_summary>
	<brief_title>PK Safety Evaluation Daptomycin Children Ages 2-6 With Proven Suspected Gram-positive Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Written parental ( appropriate legal representative ) inform consent prior studyrelated procedure part normal medical care ; Male female age 2 6 year old , inclusive ; Able comply protocol duration study ; Clinically stable evidence hemodynamic instability ( defined requirement pharmacological intervention manage blood pressure ) 72 hour window prior enrollment , history evidence renal hepatic compromise ; Suspected diagnose Grampositive infection subject receive standard antibiotic therapy ; A calculate creatinine clearance rate ( CLcr ) â‰¥ 80 ml/min/1.73m2 determine Schwartz equation baseline ; Creatine phosphokinase ( CPK ) level less 2X ULN ( upper limit normal ) baseline . Presence two patent intravenous line ( comparable mean venous access ) prior dose Study Day 1 . Investigational drug use ( include daptomycin ) participation experimental procedure 30 day precede study entry ; Known allergy/ hypersensitivity daptomycin ; History clinically significant cardiovascular , renal , hepatic , pulmonary ( wellcontrolled asthma acceptable ) , gastrointestinal , endocrine , hematologic , autoimmune disease primary immune deficiency ; Pneumonia sole Grampositive infection treat standard antibiotic ; Subjects clinically significant abnormal laboratory test result [ include electrocardiogram ( ECGs ) ] , determine Investigator ; Administration rifampin within 7 day study drug administration ; Body mass index ( BMI ) outside 5th 95th percentile ; Subjects collection require blood volume would put risk hemodynamic disturbance ( discretion Investigator ) ; History current clinically significant ( discretion Investigator ) muscular disease , nervous system seizure disorder ; Administration intramuscular injection baseline study drug administration expect intramuscular injection within 24 hour follow dosing ; Expected surgical procedure ( ) within 24 hour prior follow dose ; Unexplained muscular weakness , history peripheral neuropathy , GuillianBarre spinal cord injury ; History current rhabdomyolysis .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>